London Drugs Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by London Drugs and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 7200 London Drugs employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that London Drugs has purchased the following applications: 6sense Account Engagement Platform for Account Based Marketing in 2023, Microsoft BI (SSRS, SSAS, SSIS, SQL Server Reporting) for Analytics and BI in 2006, Microsoft Azure Cloud Services for Application Hosting and Computing Services in 2021 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems London Drugs is running and its propensity to invest more and deepen its relationship with 6sense , Microsoft , Cisco Systems or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing London Drugs revenues, which have grown to $2.00 billion in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for London Drugs intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.